vemurafenib inn sold brand name zelboraf medication used treatment latestage inhibitor braf enzyme developed vemurafenib causes programmed cell death melanoma cell vemurafenib interrupts brafmek step brafmekerk pathway braf common mutation vemurafenib works melanoma patients whose cancer braf mutation amino acid position number braf protein normal valine replaced glutamic melanomas mutation also efficacy rarer braf mutation melanoma cells without mutations inhibited vemurafenib drug paradoxically stimulates normal braf may promote tumor growth three mechanisms resistance vemurafenib covering cases discovered maximum tolerated dose mtd mg twice day patients get skin lesions may need surgical trial investigated patients common adverse events arthralgia patients skin rash photosensitivity order better manage side effects form dose modification necessary patients median daily dose mg phase clinical study vemurafenib known able reduce numbers cancer cells half group patients advanced melanoma treated group median increased survival time months control second phase study patients mutation braf showed partial complete regression regression lasted early phase solid tumors including colorectal cancer phase ii study metastatic melanoma phase iii trial vs dacarbazine patients previously untreated metastatic melanoma showed improved rates overall progressionfree june positive results reported phase iii brafmutation melanoma trial reported good updated results trials planned including trial vemurafenib coadministered cobimetinib good results combination submitted european medical agency us food drug administration marketing january trial results compared vemurafenib combination dabrafenib trametinib metastatic vemurafenib approved united states treatment latestage melanoma august making first drug designed using fragmentbased lead discovery gain regulatory vemurafenib approved use canada february february european commission approved vemurafenib monotherapy treatment adults braf mutation positive unresectable metastatic melanoma aggressive form skin november us food drug administration fda approved vemurafenib treatment people disease ecd rare type histiocytic trial combining vemurafenib ipilimumab stopped april signs liver grant hairy cell leukemia foundation supported discovery braf mutation classic hcl discovery charted new path forward many patients improved diagnosis opened door additional therapies used managing phase ii clinical trial memorial sloan kettering testing vemurafenib plus obinutuzumab patients previously untreated classical hairy cell separate clinical study treatment vemurafenib monotherarpy demonstrated high response rates relapsedrefractory rr hairy cell leukemia hcl achieving overall response rate including complete response cr partial response however median followup months responders experienced relapse median relapsefree survival rfs months range httpsenwikipediaorgwikivemurafenib